At ProFound, we're a team of pioneers dedicated to our #ProFoundPurpose of illuminating the #ExpandedProteome to unlock new therapeutic possibilities for patients. Visit our careers page for open opportunities to make a profound impact on human health: https://bit.ly/3ZPH5NX
ProFound Therapeutics
生物技术
Pioneering the expanded human proteome to reveal a universe of new medicines.
关于我们
ProFound Therapeutics is pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines. The company’s ProFoundry Platform uses state-of-the-art protein detection technologies to systematically identify and validate proteins and dissect their therapeutic potential. The result is an ever-expanding database of tens of thousands of novel proteins, including their connectivity, functionality, and roles in health and disease. ProFound Therapeutics was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.
- 网站
-
https://www.profoundtx.com/
ProFound Therapeutics的外部链接
- 所属行业
- 生物技术
- 规模
- 11-50 人
- 类型
- 私人持股
- 创立
- 2022
ProFound Therapeutics员工
-
Avak Kahvejian
General Partner @ Flagship Pioneering | Biotech Innovator & Entrepreneur
-
Tony Manning PhD
Principal at Manning Bio Worldwide LLC
-
Yvette R. Terry, M.Ed.
Executive Assistant | Helping Presidents & CEOs Achieve Successful Outcomes
-
Klaus Urbahns
Pioneering the expanded human proteome
动态
-
On his one-year anniversary with ProFound, our CEO, John Lepore, MD, was featured in an episode of BiotechTV hosted by Brad Loncar. Continue watching to hear how we’re pioneering the exploration of the #ExpandedProteome to unveil new drugs and drug targets to develop potential first-in-class medicines for patients.
?????????????? ??????????????: Flagship's ProFound Therapeutics is searching for proteins for use as therapeutics and targets beyond those found in the traditional protein coding regions of DNA. CEO John Lepore, MD, who was previously head of research at GSK, describes how the company is screening all proteins that are made by ribosomes, and then tests the functionality of novel ones to see if they can be harnessed as therapeutics or new drug targets. Full video: https://lnkd.in/gdqqYVX5 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
We had such a fun night celebrating our #Fierce15 win at the Fierce Biotech awards ceremony! We’re proud of the achievements our team has accomplished to date and are even more excited about what lies ahead as we pioneer the #ExpandedProteome and advance our #ProFoundPurpose of bringing new therapies to patients.
-
Next week, our CEO, John Lepore, is joining a panel at the Mass General Brigham Innovation World Medical Innovation Forum. Stop by to learn about new innovations being developed to address the many patient needs that remain unmet. #WMIF2024
-
?? Mark your calendars! Our CEO, John Lepore, is moderating a panel at the BioCentury Inc. Grand Rounds R&D conference. Listen in on the discussion to learn about the role of causal #biology in achieving preclinical validation. More about the panel here: https://lnkd.in/gti9bfMf?#BioCenturyGrandRounds
-
We’re thrilled to announce our Chief Innovation Officer, Vinidhra Mani has been named a 2024 Boston Business Journal 40 under 40 honoree! As a founding team member, Vini’s leadership and contributions have been invaluable to our rapid growth and success illuminating the #ExpandedProteome. We're honored to have her as a member of the ProFound team and look forward to the continued impact she'll have in the world of #biotech and the Greater Boston community. Congratulations to all the honorees. Check out the full list here: https://bit.ly/3MpEm5X #BBJ4040
-
Interested in learning about the novel proteins hidden within our genome? “The Secret Life of DNA” panel at SXSW 2025 will offer an exciting glimpse into the mysteries of DNA and explore how new genetic discoveries are driving the next generation of medicines. With featured panelists including our CEO John Lepore, Geoffrey von Maltzahn, founding CEO Quotient Therapeutics, and Dr. Richard Young, professor at Whitehead Institute and MIT Department of Biology, the discussion will bring new insights into the efforts to further our understanding of human biology and what it means for the future of medicine. ? Cast your vote for the panel using SXSW’s #PanelPicker through August 18th:?https://lnkd.in/gSj5259D
-
We’re thrilled to announce Fierce Biotech has selected us as a 2024 #Fierce15 #biotech company! This year, we have rapidly advanced our ProFoundry? Platform, most recently showcased by our exploration agreement with Pfizer and Pioneering Medicines to uncover novel potential treatments for #obesity. Learn more about how our team is pioneering the #ExpandedProteome, identifying novel proteins with the possibility to bring new therapeutic options to patients: https://lnkd.in/egAAqe6D
-
Interested in learning more about our novel approach to advancing first-in-class medicines for nearly any disease? Listen to the latest episode of the Bioprocess Online #BusinessOfBiotech podcast where our CEO, John Lepore, dives into our mission of pioneering the #ExpandedProteome and how we're uncovering a universe of new therapeutic possibilities to bring life-changing therapies to patients worldwide. Check out the episode here: https://lnkd.in/g3tNx3rP
-
Flagship Pioneering has successfully raised $3.6 billion to advance groundbreaking innovations that will transform human health and sustainability. As a #FlagshipFounded company, we’re proud to be pioneering the #ExpandedProteome and executing our vision of expanding therapeutic possibilities to address unmet patient needs.
Flagship?Pioneering raises $3.6 billion to fuel critical breakthroughs in human health and sustainability. This expanded capital pool will accelerate the impact of original science and the creation and development of an estimated 25 breakthrough companies in human health, sustainability, and artificial intelligence. Hear from Flagship?Founder and CEO Noubar Afeyan about?how we're?taking #BiggerLeaps by leveraging the power of generative AI,?forging?novel partnerships?with pharma to speed drug development, expanding globally, and?promoting?and hiring?top talent to our leadership ranks.?Read the full press release:?https://bit.ly/4eQfx05